- Dissemination of results in progress
Prevention and treatment of opioid use disorder (OUD) has become an urgent public health priority in Canada.
Although methadone has long been the standard of care for the treatment of opioid use disorder in Canada, there is growing consensus that the superior safety profile of buprenorphine/naloxone, as well as other comparative advantages, supports its use as a first-line therapy for opioid use disorder. The OPTIMA trial aims to evaluate these two treatment options within a Canadian practice‐based framework, generating evidence that is directly relevant to a recognized national priority in public health.
Evaluate and compare the effectiveness of two different models of care for the treatment of prescription opioid use disorders (methadone and buprenorphine/naloxone) to improve patient care.